USPSTF Issues Final Recs on Youth Depression Screening

Share this content:
USPSTF Issues Final Recs on Youth Depression Screening
USPSTF Issues Final Recs on Youth Depression Screening

MONDAY, Feb. 8, 2016 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in children aged 12 to 18 years, but the evidence is currently inadequate to assess the balance of benefits and harms of screening for younger children. These findings form the basis of a final recommendation statement published online Feb. 9 in the Annals of Internal Medicine.

In order to update the 2009 USPSTF recommendation on screening for MDD in children and adolescents, Albert L. Sui, M.D., M.S.P.H., and colleagues from the USPSTF reviewed the evidence on the benefits and harms of screening. They examined the accuracy of screening tests, as well as the benefits and harms of treatment with psychotherapy, medications, and collaborative care models.

The Task Force recommends MDD screening for adolescents aged 12 to 18 years. To ensure accurate diagnosis, effective treatment, and appropriate follow-up, screening should be implemented with adequate systems in place (B recommendation). For children aged 11 years and younger, the USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of MDD screening.

"There is not enough evidence for the Task Force to make a recommendation for or against screening for major depressive disorder in children 11 and younger," USPSTF member Alex Kemper, M.D., M.P.H., said in a statement. "However, it is important to take any concern about depression seriously, regardless of age."

Recommendation Statement
Evidence Review

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths